INmune Bio Inc., a pioneering clinical stage immuno-oncology company, is thrilled to announce a significant funding milestone of $19,000,000. This strategic investment not only reinforces the scientific community’s confidence in INmune Bio’s innovative approach to cancer treatment but also fuels the next phase of advancement for its lead product, INKmune. INmune Bio is dedicated to harnessing the body’s innate immune defenses, particularly the power of natural killer (NK) cells, to combat cancer. With INKmune, the company is focused on priming these vital cells to target and eliminate residual disease—the cancer cells that survive initial treatment protocols and can lead to relapse. By targeting these resilient cells, INKmune has the potential to extend patient survival and improve overall long-term outcomes.
The newly raised funds will be primarily allocated to the further development of INKmune, enhancing its precision medicine approach and refining its novel mechanism of action. This investment will also support the initiation of critical clinical trials and the expansion of research into additional promising drug candidates, such as XPro1595, Quellor, LIVNate, and INB03. As INmune Bio continues to push the boundaries of immuno-oncology research, this funding round marks a pivotal step toward establishing a new standard in cancer therapy. Inmune Bio remains committed to transparency and scientific rigor, while acknowledging that all drug candidates have yet to be proven safe or effective in the regulatory environment. This success not only represents a leap forward in the fight against cancer but also underscores the transformative potential of innovative immunotherapies in modern medicine.
